Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Lyell Immunopharma (LYEL) Return on Sales: 2021-2023

Historic Return on Sales for Lyell Immunopharma (LYEL) over the last 3 years, with Sep 2023 value amounting to -3.76%.

  • Lyell Immunopharma's Return on Sales rose 176.00% to -3.76% in Q3 2023 from the same period last year, while for Sep 2023 it was -3.76%, marking a year-over-year increase of 176.00%. This contributed to the annual value of -2.13% for FY2022, which is 1793.00% up from last year.
  • According to the latest figures from Q3 2023, Lyell Immunopharma's Return on Sales is -3.76%, which was up 6.10% from -4.01% recorded in Q2 2023.
  • Lyell Immunopharma's Return on Sales' 5-year high stood at -2.02% during Q1 2023, with a 5-year trough of -25.89% in Q1 2022.
  • Its 3-year average for Return on Sales is -12.16%, with a median of -5.52% in 2022.
  • As far as peak fluctuations go, Lyell Immunopharma's Return on Sales tumbled by 326bps in 2022, and later soared by 2,388bps in 2023.
  • Quarterly analysis of 3 years shows Lyell Immunopharma's Return on Sales stood at -20.06% in 2021, then soared by 1,793bps to -2.13% in 2022, then soared by 176bps to -3.76% in 2023.
  • Its Return on Sales stands at -3.76% for Q3 2023, versus -4.01% for Q2 2023 and -2.02% for Q1 2023.